Study of the Dynamics of Diflunisal Release from a Polymer Matrix
Open Access
- 29 January 2024
- journal article
- research article
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 13 (1) , 75-80
Abstract
Introduction. The effectiveness of diflunisal in the treatment of cardiac amyloidosis has been clinically proven. Currently, only tablet forms of diflunisal are registered in the world, however, long-term use of NSAIDs leads to characteristic side effects. Therefore, delivery systems for diflunisal (including a form for external use) are now being actively developed to reduce side effects and improve its bioavailability.Aim. Research of the dynamics of release of the active substance diflunisal from the polymer matrix of hyaluronic acid.Materials and methods. The objects of the study are diflunisal gels in hyaluronic acid with a concentration of the main substance of 0.093, 0.14, 0.19 and 0.25 %. Quantitative determination was carried out by reverse-phase HPLC using a Prontosil C18, 120-5, 75 × 2 mm chromatographic column, thermostatically controlled at 40 °C. Eluent: phosphate buffer solution (PBS) with pH 3.0 and acetonitrile (30 : 70), flow rate 0.1 ml/min. Eluates were detected at wavelengths of 230, 270, 310 nm.Results and discussion. During the work, a method (HPLC) was selected and a method for determining diflunisal in a HA matrix was developed. The delivery system under study significantly increases the solubility of diflunisal in an aqueous solution compared to the dissolution of the substance. The release of the active substance from the matrices was carried out in a phosphate buffer solution with pH 7.6. The release rate for all samples exceeded 90 % after 3 hours after the start of the experiment, with most of the active substance released within an hour.Conclusion. The data obtained suggest that the release profile is characteristic of biodegradable matrices and diffusion-controlled delivery systems. Complete extraction of diflunisal from HA was achieved using PBS with pH 7.6 as a dissolution medium.Keywords
This publication has 19 references indexed in Scilit:
- What's new about the mechanism of methotrexate action in psoriasis?British Journal of Dermatology, 2018
- Drug Release Properties of Diflunisal from Layer-By-Layer Self-Assembled κ-Carrageenan/Chitosan Nanocapsules: Effect of Deposited LayersPolymers, 2018
- Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center’s experienceAmyloid, 2018
- pH in nature, humans and skinThe Journal of Dermatology, 2018
- TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac AmyloidosisCirculation: Heart Failure, 2018
- Crystalline inclusion complexes formed between the drug diflunisal and block copolymersChinese Chemical Letters, 2017
- Formulation, characterisation andin vivoevaluation of lipid-based nanocarrier for topical delivery of diflunisalJournal of Microencapsulation, 2016
- First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathyCurrent Opinion in Neurology, 2016
- Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosisAmyloid, 2014
- Drug Delivery Devices Based on Mesoporous SilicateDrug Delivery, 2004